Skip to content
DataLookout
Menu

AD-SysNCT05098821

Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 2 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Dec 31, 2025 to Nov 8, 2024
    • Secondary endpoints: details revised at 2 of 3 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Comparison of T-cell inflammatory markers
Timeframe: 1 year

Secondary (3)

Different T-cell pattern with dupilumab therapy
Assign recognition patterns to clinical symptoms
Connection of molecular profile and phenotype

Arms and interventions

Dupilumab treated Patients

Patients with atopic dermatitis with indication for dupilumab treatments will be observed

Other: not applicable, observational study

Sites

1 site in 1 country

  • Dpt of Dermatology and Allergology, Charité - Universitätsmedizin BerlinBerlin, Germany